Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor

被引:19
作者
Ernestam, S [1 ]
Klint, EA
Catrina, AI
Sundberg, E
Engström, M
Klareskog, L
Ulfgren, K
机构
[1] Karolinska Univ Hosp, Dept Rheumatol, S-14186 Huddinge, Sweden
[2] Karolinska Univ Hosp, Dept Med, Rheumatol Unit, Karolinska Inst, Stockholm, Sweden
[3] Karolinska Univ Hosp, Dept Med, Pediat Rheumatol Res Unit, Dept Women & Child Hlth, Stockholm, Sweden
关键词
D O I
10.1186/ar1871
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Blockade of tumour necrosis factor (TNF) is an effective treatment in rheumatoid arthritis (RA), but both non-responders and partial responders are quite frequent. This suggests that other pro-inflammatory cytokines may be of importance in the pathogenesis of RA and as possible targets for therapy. In this study we investigated the effect of TNF blockade (infliximab) on the synovial expression of IL-15 in RA in relation to different cell types and expression of other cytokines, to elucidate whether or not IL-15 is a possible target for therapy, independently of TNF blockade. Two arthroscopies with multiple biopsies were performed on nine patients with RA and knee-joint synovitis before and after three infusions of infliximab (3 mg/kg). Synovial biopsies were analysed with immunohistochemistry for expression of IL-15, TNF, IL-1 alpha, IL-1 beta and IFN-gamma, and for the cell surface markers CD3, CD68 and CD163. Stained synovial biopsy sections were evaluated by computerized image analysis. IL-15 expression was detected in all synovial biopsies taken at baseline. After infliximab therapy, the expression of IL-15 was increased in four patients and reduced in five. Synovial expression of IL-15 was not correlated with any CD marker or with the presence of any other cytokine. Synovial cellularity was decreased after 8 to 10 weeks of treatment with a significant reduction of the CD68-positive synovial cells, whereas no significant change was seen in the number of CD3-positive T cells and CD163-expressing macrophages. The number of TNF-producing cells in the synovial tissue at baseline was correlated with a good response to therapy. Thus, in this study the synovial expression of IL-15 in RA was not consistently influenced by TNF blockade, being apparently independent of TNF expression in the synovium. Consequently, we propose that IL-15 should remain as a therapeutic target in RA, regardless of the response to TNF blockade.
引用
收藏
页数:8
相关论文
共 23 条
  • [1] Targeting interleukin-15 in patients with rheumatoid arthritis - A proof-of-concept study
    Baslund, B
    Tvede, N
    Danneskiold-Samsoe, B
    Larsson, P
    Panayi, G
    Petersen, J
    Petersen, LJ
    Beurskens, FJM
    Schuurman, J
    van de Winkel, JGJ
    Parren, PWHI
    Gracie, JA
    Jongbloed, S
    Liew, FY
    McInnes, IB
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : 2686 - 2692
  • [2] Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints - Extended report
    Catrina, AI
    Trollmo, C
    af Klint, E
    Engstrom, M
    Lampa, J
    Hermansson, Y
    Klareskog, L
    Ulfgren, AK
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (01): : 61 - 72
  • [3] Effector function of type II collagen-stimulated T cells from rheumatoid arthritis patients - Cross-talk between T cells and synovial fibroblasts
    Cho, ML
    Yoon, CH
    Hwang, SY
    Park, MK
    Min, SY
    Lee, SH
    Park, SH
    Kim, HY
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (03): : 776 - 784
  • [4] The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis - Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
    Clair, EWS
    Wagner, CL
    Fasanmade, AA
    Wang, B
    Schaible, T
    Kavanaugh, A
    Keystone, EC
    [J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (06): : 1451 - 1459
  • [5] Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis
    Ferrari-Lacraz, S
    Zanelli, E
    Neuberg, M
    Donskoy, E
    Kim, YS
    Zheng, XX
    Hancock, WW
    Maslinski, W
    Li, XC
    Strom, TB
    Moll, T
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 173 (09) : 5818 - 5826
  • [6] Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rhe'umatoid arthritis
    Groh, V
    Brühl, A
    El-Gabalawy, H
    Nelson, JL
    Spies, T
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (16) : 9452 - 9457
  • [7] TLR2 is expressed on activated T cells as a costimulatory receptor
    Komai-Koma, M
    Jones, L
    Ogg, GS
    Xu, DM
    Liew, FY
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (09) : 3029 - 3034
  • [8] Quantification of the cell infiltrate in synovial tissue by digital image analysis
    Kraan, MC
    Haringman, JJ
    Ahern, MJ
    Breedveld, FC
    Smith, MD
    Tak, PP
    [J]. RHEUMATOLOGY, 2000, 39 (01) : 43 - 49
  • [9] Infliximab and methotrexate in the treatment of rheumatoid arthritis
    Lipsky, PE
    van der Heijde, DMFM
    St Clair, EW
    Furst, DE
    Breedveld, FC
    Kalden, JR
    Smolen, JS
    Weisman, M
    Emery, P
    Feldmann, M
    Harriman, GR
    Maini, RN
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) : 1594 - 1602
  • [10] Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:: a randomised phase III trial
    Maini, R
    St Clair, EW
    Breedveld, F
    Furst, D
    Kalden, J
    Weisman, M
    Smolen, J
    Emery, P
    Harriman, G
    Feldmann, M
    Lipsky, P
    [J]. LANCET, 1999, 354 (9194) : 1932 - 1939